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IWeP241I Unezolid in the treatment of patients with
nosocomial pneumonia: European results
M. Molinari!, G. Garrera l , Z. Rort2, V. Kolek3, W. DeCian l
I Infectious Diseases, Pharmada and Upjohn, Milan, Italy; 2Hospital of
Matrahaza, Matrahaza, Hungary; JUniversity Hospital Olomouc, Czech
Republic
Background: Linezolid, the first in a new class of antibacterials, the oxazo-
Iidinones, has activity against gram positive organisms, both susceptible and
resistant. This trial evaluated linezolid, in combination with aztreonam, for
the treatment of nosocomial pneumonia (NP).
Methods: This double blinded, randomized study in patients with NP
compared the efficacy of linezolid (LZD) 600 mg IV BID against vanco-
mycin (vanco) 1 gm IV BID. All patients received coverage for gram
negative organisms with aztreonam 1-2 gm IV every 8 hours. Patients
received treatment for 7-21 days. Follow-up occurred at 12-28 days after
end oftberapy.
Results: In this global trial 396 patients were treated. 119 clinically evaluable
(CE) patients were from Europe. In these European patients, LZD clinically
cured 74.6% (44/59) versus 69.0% (40/58) of the vanco treated patients
(excluding missing and indeterminate outcomes). This was comparable to
outcomes seen in the global population. For those patients with a baseline
pathogen, LZD provided microbiologic success in 90.5% (19/21) ofpatients
versus success in 72.0% (18/25) ofthe vanco treated patients. Adverse events
were generally mild to moderate in nature, with diarrhea being the most
common drug-related event.
Conclusion: Linezolid with concomitant gram negative coverage is an
effective, well-tolerated agent in treatment of NP.
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IWeP242I Eect of step-down therapy of ceftriaxone plus
loracarbef versus parenteral therapy of ceftriaxone on the
intestinal microflora in patients with community-acquired
pneumonia
F. VogelI , G. Boden2, I. Nilsson-Ehle3, I. Odenholt4, C. E. Nords
IKrankenhaus Hojheim; 2Krankenhaus Bad Homburg, Germany; JUniv . Hosp.
Lund; 4Univ. Hosp. Uppsala; sKarolinska Inst., Stockholm, Sweden
Objectives: To compare tbe effect of two antibiotic regimens on the
intestinal microflora in patients with community-acquired pneumonia.
Methods: Twenty-five newly hospitalized patients with community-
acquired pneumonia participated in the investigation. Thirteen patients
received step-doWD therapy: initial treatment with ceftriaxone 1 g intrave-
nously q 24 h for 2 days followed by oralloracarbef 400 mg q 12 b for
additional 8 days. Twelve patients were given only parenteral therapy:
ceftriaxone 1 g intravenously q 24 h for 10 days. Stool samples were obtained
(1) before treatment, (2) on day 3 of treatment when patients were allocated
to the two alternative treatment regimens, (3) at the post-therapy visit, and
(4) at the late post-therapy visit. The stool samples were microbiologically
analyzed.
Results: In the patients receiving ceftriaxone, there was a significant
suppression of enterobacteria, bifidobacreria and clostridia, while there
was a pronounced overgrowth of enterococci and candida at the same
time. The microflora had returned to normal levels at the late post-therapy
visit. The patients who were treated with the step-down therapy ceftriaxone
plus loracarbef had a reduction of Escherichia coli, bifidobacteria and
clostridia and a minor increase in the numbers of enterococci and candida.
The microflora was normalized at the last visit.
Conclusions: The step-down therapy with ceftriaxone plus loracarbef did
not cause significant ecological alterations in the intestinal microflora
compared to parenteral ceftriaxone therapy in patients with community-
acquired pneumonia.
IWeP243I cefaclor In the chemoprophylaxis of recurrent
acute otitis media in HIV-infected children
G. V. Zuccotti, E. D'Auria, M. Torcolerti, L. Tegaldo, E. Riva
Department ofPaediatrics, San Paolo Hospital, Milan, Italy
Objective: To evaluate the efficacy ofCefaclor in the chemoprophylaxis of
recurrent acute otitis media (ADM) in HIV-infecred children
Subjects: Seventeen HIV infected children (9 males, 8 females) aged 2-12
years (mean 6, SD 2.6, median 7) suffering from recurrent AOM during Oct
1997-Mar 1998 (period 1) were enrolled. The patients were given cefaclor
(20 mg/Kg) once-daily for six months (Apr-Oct 1998) (period 2); a clinical
observation was carried out in the next six months (Nov 98-Mar 99) (period
3). Natural killer activity, phagocytosis and myeloperoxidase were deter-
mined just before and at the end of the prophilaxys. For each period the
average of two CD4 count was considered for the analysis. The number of
infections occurred in the different periods was compared.
Results: The treatment was associated with a reduction of the number of
infections in 100% of cases as compared with period 1 (p < 0.0001). No
significant differences were observed between periods 2 and 3 (p = 0.62).
Antiretroviral therapy was not related to the number ofinfections in any
period: period 1 (p = 0.63), period 2 (p = 0.51) and period 3 (p = 0.55).
Moreover, no differences were observed for CD4 count among the
different periods.
A mean increase of57% of myeloperoxidase activity was also observed.
Cefaclor was well-tolerated by all the patients.
COnclusions: We hypothesize that Cefaclor may be useful in the prophy-
lactic treatment of recurrent AOM in HIV-infected children.
IWeP244I Comparison of mechanical bowel preparation with
oral sodium phosphate and antibiotic preperation in colorectal
surgery
O. Biiyiikgebiz, A. <;ubuk~, S. Giindes l , O. Ozbay
Departments ofGeneral Surgery; I Microbiology, School ofMedicine, Kocaeli
University, Kocaeli, Turkey
Oral sodium phosphate (NaP) bas become an attractive alternative to other
agents for colonic cleansing. This study was performed to evaluate the
effectiveness ofmechanical bowel preparation with NaP on wound infection
in comparison with addition of preoperative ornidazol treatment. Fiftyfive
patients with co!orectal malignancies were randomized and all underwent
elective colorectal resection. Twentynine patients were men (52%) and 26
were women with an average age of59.6±2.6 (range 30-83). Dukes' stage
was similar and the surgical procedures equally distributed in the two
groups. Female/Male ratio was 1/1.4. Group I was consisted of32 patients
who were requested to take 45 ml NaP three times in a day and oral
ornidazol 1 g b.i.d in the following day and given intravenously (i.v.)
ceftriaxon 1 g plus omidazolSOO mg preoperatively. In group n, the patients
received 90 mL of NaP twice in the day before surgery and same i.v.
profylaxis as group I. The antibiotic treatments forwarded postoperatively
in the same manner. There were two wound infections for each group which
one was located in perineum for group I. No significant difference was noted
in the incidence ofpostoperative wound infection between the two groups.
Therefore, perioperative addition ofornidazol to a good mechanical bowel
preparation was of no benefit in reducing wound infections following
surgical procedures of colorectal malignancies.
IWeP24S1 Fluoroquinolones in severe Infections In children
Daniela Leca, V. Luca, Cata!inaLuca,
Egidia Miftode
Department of Infectious Diseases, University ofMedicine and Pharmacy, Ia#,
Romania
Objectives: To demonstrate the efficiency and optimal tolerance of fluor-
oquinoloncs in the treatment ofsevere infections, sistemic and located, with
gram negative baciIli and methiciJline-sensitive Staphylococcus in children.
Method: During a 3-year period, 270 children, 115 girls and 155 boys, aged
between 19 days and 16 years, with purulent meningitis (13 cases), sepsis (40
cases) and nosocomial salmonellosis (217 cases) were studied. Sensitivity to
fluoroquinolones was found to be 90% for Staphylococcus, 99.7% for
Salmonella and 100% for Escherichia coli, Klebsiella, Proteus mirabilis. Cipro-
floxacine (210 cases), Pefloxacine (57 cases) and Ofloxacine (3 cases) were
commonly used after the failure of the first-intention antibiotic therapy
(64.4%). Fluoroquinolones were administrated in association with synergic
antibiotics in 45.5% cases in severe forms and in immunocompromised
patients (64.8%). The average time oftreatment was 17.4 days in meningitis,
21.6 days in sepsis and 6.6 days in salmonellosis. The changement of therapy
was necessary in 9 cases.
Results: We noted a great clinical and bacteriological efficiency: 90% cure in
sepsis and salmonellosis and 80% in purulent meningitis. Only 1.48%
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adverse reactions were recorded (cutaneous rash and digestive disturbance in
2 cases respectively). 18 deaths (6.6%) by septic shock were recorded.
Conclusions: Fluoroquinolones are efficient antibiotics, well tolerated,
which can be used in children as an alternative treatment in severe infections,
multiresistent germ infections and irifections in immunocompromised host.
!WeP246I Oral doxycydine treatment of Lyme
neuroborreliosis - A cerebrospinal fluid follow-up study
L. Dotevall, 1. Hagberg
Department of Infectious Diseases, Sahlgrenslea University Hospital/Ostra,
GOteborg, Sweden
Objectives: To evaluate cerebrospinal fluid (CSF) findings and clinical
efficacy of oral doxycycline in the treatment of patients with nervous
system manifestations of B burgdorferi sp infections.
Methods: CSF examinations and clinical evaluations were done before and
6-8 weeks after doxycycline treatment of60 p.tients during 1990-1 '197. All
patients (age 19-79 yrs; median 57) had verified Lyme neuroborreliosis with
meningitis .nd other neurological signs. Durations ofdoxycycline treatment
were lO-17 days (mean 10 d.ys). CSF were examined for cell counts,
cytology, protein concentrations. albumin indices. protein electrophoresis,
immunoglobulin concentrations, and antibody reactions to B borgdorferi sp.
These dat. were compared with clinical findings of the patients.
Results: CSF cell count before doxycycline treatment was 6-1100 X 106/L
(median 114), and 6-8 weeks after treatment 1-45 x lO6/L (median 7). CSF
protein concentration before treatment was 260-4800 mg/L (median 1242),
and after treatment 173-1040 mg/L (median 458). All patients were found to
be clinically improved after doxycycline treatment and no relapses were
observed.
Conclusions: The CSF findings support the clinical evaluation of oral
doxycycline treatment as an effective therapy for Lyme neuroborreliosis.
IWeP247I Effect of perorally administered dinafloxacin on
the normal intestinal microflora
Herin Ohl , Charlotta Edlundl •2, Lisbeth Barkholtl , Carl-Erik Nordl
tKarolinska Institutet, Huddige University Hospital; 2Siiderto'ms hiigskola,
University College, Stockholm, Sweden
Objektives: To analyse the concentration ofc1inafloxacin in faeces and study
the effect of clinafloxacin on the intestin.1 microflora during and .fter
clinaflox.cin administration, and to study the susceptibility pattern to
c1inafloxacin ofintestinal enterobacteria. enterococci and bacteroides.
Methods: Twelve healthy volunteers received 200 mg clinafloxacin pero-
rally twice daily for 7 days. Faecal specimens were collected at defined
intervals before, during and after the administration for microbiological
analyses and antimicrobial susceptibility testing.
Results: The mean concentration of c1inafloxacin in faeces was 176 mg/kg
on day 7. The aerobic as well as the anaerobic intestinal microflora was
strongly suppressed by clinafloxacin. At day 7 all aerobic microorganisms
were eliminated in 11 subjects. The levels ofEscherichia coli were still low at
day 21, while numbers ofenterococci and other Gram-negative rods than E.
coli were increased compared to pretreatment levels. Nine subjects became
colonised with Candida spp. The numbers of bifidobacreria. clostridia and
Bacteroides spp. decreased significantly during administration. At day 21 the
levels of clostridia were higher, while the numbers of Bacteroides spp. were
lower than before treatment. One subject became colonised with Clostridium
difficile. No development ofresistance was seen for enterococci, while MIC-
values for Enterobacteriaceae and Bacteroides spp. increased significantly
during administration.
Conclusions: In the present study administration ofc1inafloxacin resulted in
marked disturbances in the intestinal microflora. Resistant strains of Enter-
obacteriaceae and Bacteroides spp. emerged during administration.
IWeP248I Piperacillinltazobactam vs. cefotaxime and
metronidazole for severe intra-abdominal infections in children
D. AdamI, T. Linglof, D. FloretJ
Tazocin Pediatric Infection Study Group; 'Killderspital, Munich, Germany;
2University Hospital, Uppsala, Sweden; 3Hospital E. H. Place d'Arsonval.
Lyon, France; European and African Hospital Centas
Objectives: To compare the efficacy and safety of piperacillin/tazobaetam
(pip/tazo) monotherapy and combination therapy with cefotaxime (ceQ and
metronidazole (met) in hospitalized pediatric patients (pts) with clinically or
bacteriologically diagnosed severe intra-abdominal infection.
Methods: An open-label. phase III study randomized pts pre-surgery to
receive pip/tazo 100/12.5 mg/kg (n = 263) or cefSO mg/kg and met 7.5 mgt
kg (n = 258), each administered IVq8h. Treatment (trt) dUr3tion for efficacy
evaluable pts was a minimum of 2 days to declare failure and 5-14 days to
declare clinical cure. Follow-up continued for about 2 wks post-trt. Primary
clinical endpoint w.s Cure (trt completed, no clinical evidence ofinfection)
or Failure (no response, or deterioration, or further antibacterial trt or
surgery, or new pathogen, or death) assessed at the test-of-cure visit by an
independent committee blinded to trt. Bacteriologic response in the popula-
tion with an identified baseline pathogen was a secondary endpoint.
Results: Equivalence was b.sed on a 95% confidence interv.1 and an
equiv.lencc limit set at -lO%. Equivalence of pip/tazo compared to cef
and met was established for clinical cure (181/201 pts, 90.0% vs 183/201 pts,
91.0%, respectively) and bacteriological response (134/152 pts, 88.2% vs
139/155 pts, 89.7%, respectively). Both regimens were well tolerated,
Conclusions: Pip/tazo monotherapy should be considered an effective
ther.peutic option for children with severe intr3-abdominal infections.
[WeP249! Antimicrobial resistance among pathogens of
patients hospitalized with pneumonia in Europe: Results from
the SENTRY antimicrobial surveillance program 1997-1998
A. c. F1uit,J. Verhoef, F. -J. Schmitz
For the SENTRY Participants Group; Eijkman-Winkler Inst., Univ. Med.
Center Utrecht, Utrecht, Netherlands
The SENTRY antimicrobial surveillance-program was estabIished to
monitor the occurrence and antimicrobial susceptibility of bacterial patho-
gens via an international network of sentinel hospitals. Twenty European
hospitals forwarded a total of 2107 nosocomial pneumonia isolates to a
reference laboratory for testing against various antimicrobial agents by broth
microdllution method. The most frequently isolated species were Staphylo-
coccus aureus (21.0%), Pseudomonas aeruginosa (20.3%), EnleTobaaer spp.
(7.9%), Escherichia coli (7.0%). Streptococcus pneumoniae (5.7%). Haemophilus
injluellzae (4.7%), Acinetobacter spp. (4.4%), Klebsiella pneumoniae (4.3%).
Serratia spp. (3.8%). and Stenotrophomonas maltophilia (2.6%). Pseudomonas
aeruginosa showed the highest susceptibility to amikacin (91 %), closely
followed by piperacillin/tazobactam. cefepime, and meropenem (87-89%
susceptibility). The Enterobacteriaceae showed good susceptibility to the
carbapenems (98-100%), cefepime and amikacin (borh 93-100% suscept_
ibility). Susceptibility to the f1uoroquinolones ranged between 83 and 98%.
The majority of pneumococcal isolates was susceptible to penicillin (73%),
15% was intermediate-resistant and 15% high level-resistant. All pneumo-
cocal isolates were completely susceptible to f1uoroquinolones, rifampin. and
vancomycin. Haemophilus injluellzae isolates were fully susceptible to both
f1uoroquinolones and cephalosporins. One third of the Staphylococcus aureus
isolates was resistant to oxacillin. Susceptibility to vancomycin was complete
(100%).
IWeP250Icarbapenems in the treatment of septic surgical
complications
J. Meszaros, G. Michalak, M. Kosieradzki, G. Krasowski, A. Sawicka, A.
Rokosz, H. Misiurewicz-Stypulkowska
Department ofGeneral & Transplalltation Surgery, Medical University of
Warsaw & National Institute ofHygiene, Warsaw, Poland
An open and prospective study on carbapenem efficacy in septic surgical
complications - mainly intraabdominal infections. septicemia and pneumo-
nia with acute respiratory insufficiency (ARI) - was performed in 1996-'19.
Two hundred and seventy-eight pts were treated with imipenem/cilastatin
and 80 pts with meropenem. Study inclusion criteria: severe progressing
sepsis, non-successful previous antibiotic ther3py and resistance to cephalos-
porins. Among isolated pathogens, gram-negatives prevailed (72%), with
Pseudomonas, Enterobacter, Acinetobart.... Proteus spp. and K. pneumoniae.
Staphylococci and enterococci were less common (15%). Anaerobes (13)%
were mainly isolated in pts requiring abdominal reoperation for sepsis.
Susceptibility ofaerobic and anaerobic isolates w.s about 95%. Carbapenem
therapy had to be modified in 40% pts. because of superinfections with
Calldida spp, S. aureus (MRSA), enterococci, C. difficile and S. maltophilia.
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Efficacy of the treatment was similar for imipenem and meropenem (79%
and 81 %). Mortality rate in both groups (18%) was closely related to clinical
disease and was higher (about 45%) in septic complications of acute
pancreatitis and pneumonia with ARI. Our clinical experience with carba-
penems confirmed their value in empiric therapy of septic surgical compli-
cations.
but have not yet reached 112 weeks of follow-up. Significantly fewer
patients in the EFV + ZDV + 3TC arm required discontinuation for
adverse events (P ::; .05).
Conclusions: The combination of EFV + ZDV + 3TC continues to
demonstrate superior efficacy, durability and tolerability over IDV +
ZDV + 3TC in patients treated over a prolonged period of time.
CD4 < 100 CD4 ~ 100 CD4 < 100 CD4 ~ 100
EFV + ZDV + 3TC 67.5%* 69.4%* 55.0% 63.9%*
(27/40) (202/291) (22/40) (188f294)
EFV + mv 34.2% 58.0%t 23.1% 53.0%t
(13/38) (171/295) (9/39) (157f296)
IDV + ZDV + 3TC 45% 49.2% 35.0% 44.3%
(18/40) (152/309) (14/40) (139/314)
* p < 0.05 EFV + ZOV + 3TC v, IOV + ZOV + 3TC: t p < 0.5 F.FV + mv
vs mv + ZDV + 3TC
Condusions: Patients with baseline CD4 counts < 100 cells/mm3 treated
with EFV + ZDV + 3TC demonstrated similar response rates through 48
weeks as those with higher baseline CD4 counts. EFV + ZDV + 3TC
maintained its superiority over IDV + ZDV + 3TC even in patients with
low CD4 counts at baseline.
HIV-RNA < 50 cpmHIV-RNA < 400 cpm
IWeP253I Successful virologic suppression with Efavirenz in
HIV-infected patients with low baseline CD4 cell counts: Post hoc
results from Study 006
M. Nelsonl , S. Staszewski2,). O. Morales-Ramirez3, C. B. Aguado·, D.
P. PalterS, F. Milazz06,]. L. Touraine7, T. O. Saint Marc7, D. R. Farina8,
L.). 8essen8, N. M. Ruiz8
Study 006 Team; 1St. Stephen's Centre, London, United Kingdom; 2Klinikum
derJ. W. Goethe-Universitat, Frankfurt, Germany; JClin. Res. Puerto Rico,
Inc., Sanjuan, PR, United States; <Hospital de Mos/oles, Madrid; 5Cuidad
Sanitaxia de Bel/vitge, Barcelona, Spain; 6Luigi Sacco Hospital, Milan, Italy;
7Hospital Edouard-Herriot, Lyon, France; 8DuPont Pharma. Co., Wilmington,
Gmnany
Background: Efavirenz (EFV, SUSTIVA18) with NRTis demonstrates
similar response rates in patients with baseline viral loads above and below
100,000 copies/mi. The objective of this analysis is to explore the antiviral
activity and efficacy of EFV in therapy-naIve patients with baseline CD4
counts < 100 cells/mm3.
Methods: Post hoc analysis ofStudy 006, N = 1266 PI, NNRTI-and 3TC-
naive patients. Baseline characteristics for patients with CD4 < 100 cells/
mm3: male-84%; caucasian-60%; mean age-39.3 (±8.7); mean HIV-1
RNA (VL)-5.32 log10 copies/mL (epm) (208,930 epm); mean CD4- 63.6
cells/mm3.
Results: (NC = F):
IWeP254IOral oseltamivir is effective in the treatment of
acute influenza in a vaccinated population
M. Zaug1, P. Mahoney2, P. Ward2
On behalfoj the Osrltamivir Study Group; 'F. Hoffmann-La Roche, Base/,
Switzerland; 2Roche, Welwyn, United Kingdom
Objective: Oseltamivir, the oral prodrug of the neuraminidase inhibitor
GS4071, has previously demonstrated efficacy in treatment ofacute influenza
in otherwise healthy unvaccinated patients. Elderly or patients with chronic
cardiac/respiratory disease are considered to be at risk for significant
morbidity and mortality associated with influenza infection. However,
vaccination does not provide complete protection and vaccinated patients
may still develop influenza illness. Thw there is need for an effective antiviral
treatment for the vaccinated population. We evaluated the benefits of
oseltamivir in the treatment of influenza in a vaccinated 'at risk' population
including the elderly and patients with chronic cardiac/respiratory disease
(aged> 13).
Methods: Vaccinated patients presenting with acute febrile influenza illness
< 36 h after onset of symptoms received oseltamivir 75 mg bid or placebo
for 5 days. Symptoms were scored twice daily on a diary card (0 = absent, 1
= mild, 2 = moderate, or 3 = severe). The endpoint was the time to
-
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IWeP251I Probiotic supplementation during administration of
cefpodoxime proxetil
K. Orrbage1, S. Sjostedt2, C. E. Nordl
,Departments ofMicrobiology, Pathology and Immunology; 2Surgery, Huddinge
University Hospital, Karolinska Institutet, Stockholm, Sweden
Objectives: To study the intestinal microflora and clinical status in healthy
volunteers during administration of cefpodoxime proxetil with or without
supplements of Bifidobaclerium longum and Lutobacillus acidophilus and
oligofructose.
Methods: Three groups ofhealthy volunteers with 10 persons each received
cefpodoxime proxetil perorally bid for 7 days. One of the groups also
received a fermented milk product with 1011 CFU of B. Iongum BB 536 and
L. acidophilus NCFB 1748 and IS g oligofructose daily, another group had
only oligofructose and the last group received a placebo product, for 21 days.
Fecal samples were collected for microbiological analyses and clinical status
of volunteers was recorded.
Results: In the lactic acid bacteria administered group Clostridium d!fficile
was found in only one person at one sampling occasion, whereas in the other
two groups six persons each became colonized. In the rest of the anaerobic
microflora there was a dramatic decrease in microorganisms on the 4th day
of administration, mainly due to a loss of bifidobaeteria in all groups. The
administered strain of bifidobacteria was recovered in one volunteer. The
number of lactobacilli also decreased but the administered strain of L.
acidophilus was identified in six persons. The treatment was well tolerated
by the volunteers and did not cause any serious side effects.
Conclusions: The administration of the two probiotic microorganisms,
capable of surviving the passage through the intestinal tract, may have
influenced the ecology of the intestinal microflora thereby decreasing the
colonization of C. difficile.
K. Tashima l , S. Staszewski2,). O. Morales-Ramirez3, A. Rachlis·, R.
StrykerS, D. R. Farina6, D.). Manion6, N. M. Ruiz6
Study 006 Team; 'The Miriam Hospital, Providence, RI, United States;
2K linikum derJ. W. Goethe-Universitat, Frankfurt, Germany; JCli". Res.
Puerto Rico, Inc., Sanjuan, PR, United States; 4Sunnybrook Health Science
Ctr, Toronto, Canada; 'Pacific Oaks Res., Beverly Hills, CA; 6DuPont
Pharma. Co., Wilmington, DE, United States
Objective: Study 006 demonstrated superior efficacy and tolerability of
efavirenz(SUSTIVAt8) + ZDV + 3TCoverlndinavir(IDV) + ZDV +
3TC at 72 weeks.
Methods: Randomized study of PI-, NNRTI- and 3TC-nalve patients;
mean HIV-1 RNA (VL)-60.256 copies/mL (epm); mean CD4 count-341
cells/mm3. KM: pts never reaching < 400 cpm assigned zero days for DOR,
otherwise DOR equal to time to VL > 400 cpm, discontinuation from
study or AIDS-defining illness.
Duration ofResponse:
P:8/3 - dinical trials of antimicrobial agents - III
IWeP252I Continued viral suppression in patients treated
with efavirenz (EFV) + zidovudine (ZDV) + lamivudine (3TC) at
112 weeks: Kaplan-Meier analyses for the extended cohort of
study 006 (n = 1266)
This analysis allows for the inclusion of data beyond 48 weeks as Kaplan-
Meier estimates by accounting for patients who are still virologic responders
